Stockreport

Immuneering Launches Pancreatic Cancer Advisory Board

Immuneering Corporation - Class A  (IMRX) 
PDF - Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug designation in pancreatic cancer and Fas [Read more]